BridgeBio Oncology Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
BBOT Nasdaq 2830 bbotx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for BridgeBio Oncology Therapeutics, Inc.

Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter - May 17th, 2026 12:33 pm
Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally - May 17th, 2026 12:25 pm
Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million More - May 17th, 2026 12:18 pm
Bicara Stock Is Up 50%, and One Biotech Investor Has Made It a 29% Portfolio Bet - May 15th, 2026 5:02 pm
Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back - May 15th, 2026 4:56 pm
Kestra Medical Grew Revenue 63%. One Fund Still Trimmed 351,000 Shares - May 15th, 2026 4:50 pm
BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress - May 12th, 2026 3:03 pm
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - May 12th, 2026 2:05 pm
Here Are Monday’s Top Wall Street Analyst Research Calls: Dell Technologies, BioMarin Pharmaceutical, Disney, HubSpot, Klarna, Oklo, Pitney Bowes, Trade Desk, Wendy’s, and More - May 11th, 2026 5:58 am
Lilly tumbles on Foundayo’s shaky week; FDA to issue vouchers for psychedelics - Apr 24th, 2026 4:46 am
BBOT Presents Preclinical Data Demonstrating pan-KRAS Inhibitor BBO-11818 Has Robust Anti-Tumor Activity in KRAS-Mutant Preclinical Models at the AACR Annual Meeting 2026 - Apr 22nd, 2026 2:05 pm
BBOT Announces the Appointment of Pedro J. Beltran, PhD, as Chief Executive Officer, Idan Elmelech as Chief Operating Officer, and Neil Kumar, PhD, as Executive Chairman - Apr 22nd, 2026 7:00 am
BBOT Presents Preclinical Data Showing RAS:PI3Kα Breaker BBO-10203 Inhibits PI3Kα/AKT Signaling in HER2AMP Models at the AACR Annual Meeting 2026 - Apr 21st, 2026 3:30 pm
BBOT Granted U.S. FDA Fast Track Designation for BBO-11818 for the Treatment of Adult Patients with Advanced KRAS-Mutant Pancreatic Ductal Adenocarcinoma - Apr 20th, 2026 2:06 pm
BBOT Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026 - Mar 18th, 2026 2:05 pm
This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know? - Mar 16th, 2026 5:56 pm
This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal - Mar 16th, 2026 5:33 pm
Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch - Mar 16th, 2026 5:02 pm
This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter - Mar 16th, 2026 4:43 pm
BridgeBio Oncology (BBOT) Spotlights Next-Gen RAS Pipeline, $425M Cash Runway Into 2028 - Mar 12th, 2026 9:18 pm